GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Machinery, Furniture, Equipment

Biogen (HAM:IDP) Machinery, Furniture, Equipment : €0 Mil (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Biogen Machinery, Furniture, Equipment?

Biogen's Machinery, Furniture, Equipment for the quarter that ended in Mar. 2024 was €0 Mil.

Biogen's quarterly Machinery, Furniture, Equipment increased from Sep. 2023 (€0 Mil) to Dec. 2023 (€2,565 Mil) but then declined from Dec. 2023 (€2,565 Mil) to Mar. 2024 (€0 Mil).

Biogen's annual Machinery, Furniture, Equipment increased from Dec. 2021 (€2,323 Mil) to Dec. 2022 (€2,523 Mil) and increased from Dec. 2022 (€2,523 Mil) to Dec. 2023 (€2,565 Mil).


Biogen Machinery, Furniture, Equipment Historical Data

The historical data trend for Biogen's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Machinery, Furniture, Equipment Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Machinery, Furniture, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,531.08 1,638.49 2,322.68 2,522.84 2,565.22

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Machinery, Furniture, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2,565.22 -

Biogen Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.


Biogen (HAM:IDP) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines